Issues Relating to Development and Management of Social Sector

GS-2

2. INDIGENOUSLY DEVELOPED DNA VACCINE CANDIDATE

DBT-BIRAC supported indigenously developed DNA Vaccine Candidate by ZydusCadila, approved for Phase III clinical trials.

IMPORTANT POINTS:

  • India’s first indigenously developed DNA vaccine candidate against COVID-19, ZyCoV-D, by ZydusCadila has been approved by the Drugs Controller General of India (DCGI), for the conduct of Phase III clinical trials.
  • The candidate has been supported by the National Biopharma Mission (NBM) under the aegis of BIRAC and the Department of Biotechnology, Government of India.
  • After phase I and II trials, ZydusCadila’s interim data indicated that the vaccine is safe and immunogenic when three doses were administered intradermally.
  • Based on the recommendations of the Subject Expert Committee, which reviewed the interim data, the DCGI has accorded permission for conducting Phase-III clinical trial in 26,000 Indian participants.
  • BIRAC Biotechnology Industry Research Assistance Council (BIRAC), set up under the Dept. of Biotechnology (DBT), is supporting the vaccine manufacturing platform establishment under the National Biopharma Mission.

SOURCE: PIB

About ChinmayaIAS Academy - Current Affairs

Check Also

NATO MEMBERSHIP FOR FINLAND AND SWEDEN

Recently, Finland and Sweden have shown interest to join the North Atlantic Treaty Organization (NATO). It …

Leave a Reply

Your email address will not be published.

Get Free Updates to Crack the Exam!
Subscribe to our Newsletter for free daily updates